Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes

Abstract Acute myeloid leukaemia (AML) patients harbouring certain chromosome abnormalities have particularly adverse prognosis. For these patients, targeted therapies have not yet made a significant clinical impact. To understand the molecular landscape of poor prognosis AML we profiled 74 patients...

Full description

Bibliographic Details

Published in:	Signal Transduction and Targeted Therapy
Main Authors:	Pedro Casado, Ana Rio-Machin, Juho J. Miettinen, Findlay Bewicke-Copley, Kevin Rouault-Pierre, Szilvia Krizsan, Alun Parsons, Vinothini Rajeeve, Farideh Miraki-Moud, David C. Taussig, Csaba Bödör, John Gribben, Caroline Heckman, Jude Fitzgibbon, Pedro R. Cutillas
Format:	Article
Language:	English
Published:	Nature Publishing Group 2023-02-01
Online Access:	https://doi.org/10.1038/s41392-022-01288-1